{"id":"https://openalex.org/W2891576167","doi":"https://doi.org/10.1200/jco.2018.36.15_suppl.tps8585","title":"Phase II trial of atezolizumab before and after definitive chemoradiation for unresectable stage III NSCLC.","display_name":"Phase II trial of atezolizumab before and after definitive chemoradiation for unresectable stage III NSCLC.","publication_year":2018,"publication_date":"2018-05-20","ids":{"openalex":"https://openalex.org/W2891576167","doi":"https://doi.org/10.1200/jco.2018.36.15_suppl.tps8585","mag":"2891576167"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2018.36.15_suppl.tps8585","doi":"https://doi.org/10.1200/jco.2018.36.15_suppl.tps8585","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2018.36.15_suppl.tps8585","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5002341560","display_name":"Helen J. Ross","orcid":"https://orcid.org/0000-0003-4280-3066","observed_orcids":["https://orcid.org/0000-0003-4280-3066"]},"institutions":[{"id":"https://openalex.org/I4210125099","display_name":"Mayo Clinic in Arizona","ror":"https://ror.org/03jp40720","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723","https://openalex.org/I4210125099"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Helen J. Ross","raw_affiliation_strings":["Mayo Clinic, Scottsdale, AZ;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mayo Clinic, Scottsdale, AZ;","institution_ids":["https://openalex.org/I4210125099"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075890039","display_name":"David Kozono","orcid":"https://orcid.org/0000-0002-8916-396X","observed_orcids":["https://orcid.org/0000-0002-8916-396X"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David E. Kozono","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083111924","display_name":"James John Urbanic","orcid":"https://orcid.org/0000-0001-6763-2780","observed_orcids":["https://orcid.org/0000-0001-6763-2780"]},"institutions":[{"id":"https://openalex.org/I36258959","display_name":"University of California San Diego","ror":"https://ror.org/0168r3w48","country_code":"US","type":"education","lineage":["https://openalex.org/I36258959"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"James John Urbanic","raw_affiliation_strings":["University of California, San Diego, Encinitas, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of California, San Diego, Encinitas, CA;","institution_ids":["https://openalex.org/I36258959"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040079785","display_name":"Terence Marques Williams","orcid":"https://orcid.org/0000-0002-1020-0845","observed_orcids":["https://orcid.org/0000-0002-1020-0845"]},"institutions":[{"id":"https://openalex.org/I2799885155","display_name":"The Ohio State University Comprehensive Cancer Center \u2013 Arthur G. James Cancer Hospital and Richard J. Solove Research Institute","ror":"https://ror.org/028t46f04","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799885155","https://openalex.org/I2802841970"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Terence Marques Williams","raw_affiliation_strings":["Ohio State University Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ohio State University Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH;","institution_ids":["https://openalex.org/I2799885155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079922057","display_name":"Carter DuFrane","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091146","display_name":"Alliance Foundation Trials","ror":"https://ror.org/00fztf021","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210091146"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Carter Dufrane","raw_affiliation_strings":["Alliance Foundation Trials, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Alliance Foundation Trials, Boston, MA;","institution_ids":["https://openalex.org/I4210091146"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110688867","display_name":"Ilze B\u0101ra","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I183934855","display_name":"Genentech","ror":"https://ror.org/04gndp242","country_code":"US","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I129302853","https://openalex.org/I183934855"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ilze Bara","raw_affiliation_strings":["Genentech, South San Francisco, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Genentech, South San Francisco, CA;","institution_ids":["https://openalex.org/I183934855"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5107196211","display_name":"Mayank Gandhi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I183934855","display_name":"Genentech","ror":"https://ror.org/04gndp242","country_code":"US","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I129302853","https://openalex.org/I183934855"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mayank Gandhi","raw_affiliation_strings":["Genentech, Inc., San Francisco, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Genentech, Inc., San Francisco, CA;","institution_ids":["https://openalex.org/I183934855"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034467403","display_name":"Katja Schulze","orcid":"https://orcid.org/0000-0003-3704-5651","observed_orcids":["https://orcid.org/0000-0003-3704-5651"]},"institutions":[{"id":"https://openalex.org/I183934855","display_name":"Genentech","ror":"https://ror.org/04gndp242","country_code":"US","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I129302853","https://openalex.org/I183934855"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Katja Schulze","raw_affiliation_strings":["Genentech, Inc., San Francisco, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Genentech, Inc., San Francisco, CA;","institution_ids":["https://openalex.org/I183934855"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023208899","display_name":"Jane Michelle Brockman","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jane Michelle Brockman","raw_affiliation_strings":["Genentech--BioOnc, Dayton, OH;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Genentech--BioOnc, Dayton, OH;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075123627","display_name":"Xiaofei F. Wang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210126298","display_name":"Duke Medical Center","ror":"https://ror.org/03njmea73","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210126298","https://openalex.org/I4210144876"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Xiaofei F. Wang","raw_affiliation_strings":["Duke University Medical Center, Durham, NC;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Duke University Medical Center, Durham, NC;","institution_ids":["https://openalex.org/I4210126298"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063904421","display_name":"Everett E. Vokes","orcid":"https://orcid.org/0000-0002-8645-8068","observed_orcids":["https://orcid.org/0000-0002-8645-8068"]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]},{"id":"https://openalex.org/I4210087865","display_name":"University of Chicago Medical Center","ror":"https://ror.org/0076kfe04","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087865"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Everett E. Vokes","raw_affiliation_strings":["Section of Hematology/Oncology, Department of Medicine, The University of Chicago Medicine, Chicago, IL;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Section of Hematology/Oncology, Department of Medicine, The University of Chicago Medicine, Chicago, IL;","institution_ids":["https://openalex.org/I40347166","https://openalex.org/I4210087865"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5014554706","display_name":"Thomas E. Stinchcombe","orcid":"https://orcid.org/0000-0002-3595-8011","observed_orcids":["https://orcid.org/0000-0002-3595-8011"]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Tom Stinchcombe","raw_affiliation_strings":["University of North Carolina at Chapel Hill, Chapel Hill, NC;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of North Carolina at Chapel Hill, Chapel Hill, NC;","institution_ids":["https://openalex.org/I114027177"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":10,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":6,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"36","issue":"15_suppl","first_page":"TPS8585","last_page":"TPS8585"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9110999703407288,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9110999703407288,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10202","display_name":"Lung Cancer Diagnosis and Treatment","score":0.07919999957084656,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.002400000113993883,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/atezolizumab","display_name":"atezolizumab","score":0.9980000257492065},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.8370000123977661},{"id":"https://openalex.org/keywords/stage-iii-non-small-cell-lung-cancer","display_name":"stage III NSCLC","score":0.968999981880188},{"id":"https://openalex.org/keywords/neoadjuvant-immunotherapy","display_name":"neoadjuvant immunotherapy","score":0.8389999866485596},{"id":"https://openalex.org/keywords/definitive-chemoradiotherapy","display_name":"definitive chemoradiotherapy","score":0.8939999938011169},{"id":"https://openalex.org/keywords/pd-l1-blockade","display_name":"PD-L1 blockade","score":0.9309999942779541},{"id":"https://openalex.org/keywords/carboplatin","display_name":"carboplatin","score":0.5979999899864197},{"id":"https://openalex.org/keywords/paclitaxel","display_name":"paclitaxel","score":0.996999979019165},{"id":"https://openalex.org/keywords/radiation-induced-immunogenicity","display_name":"radiation-induced immunogenicity","score":0.5059999823570251},{"id":"https://openalex.org/keywords/tumor-mutational-burden","display_name":"tumor mutational burden","score":0.6919999718666077},{"id":"https://openalex.org/keywords/predictive-biomarkers","display_name":"predictive biomarkers","score":0.9539999961853027},{"id":"https://openalex.org/keywords/disease-control-rate","display_name":"disease control rate","score":0.7319999933242798},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.47699999809265137},{"id":"https://openalex.org/keywords/tcr-repertoire","display_name":"T cell receptor repertoire","score":0.5149999856948853},{"id":"https://openalex.org/keywords/tumor-immune-microenvironment","display_name":"tumor immune microenvironment","score":0.5540000200271606}],"concepts":[{"id":"https://openalex.org/C2775949291","wikidata":"https://www.wikidata.org/wiki/Q20707748","display_name":"Atezolizumab","level":5,"score":0.9747110605239868},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9029239416122437},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6425332427024841},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6071683168411255},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.586707592010498},{"id":"https://openalex.org/C2781451048","wikidata":"https://www.wikidata.org/wiki/Q415588","display_name":"Carboplatin","level":4,"score":0.5235654711723328},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.437759667634964},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.43764254450798035},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.3524366021156311},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.3158612847328186},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.291483074426651},{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.2706076502799988},{"id":"https://openalex.org/C2778239845","wikidata":"https://www.wikidata.org/wiki/Q412415","display_name":"Cisplatin","level":3,"score":0.12133404612541199}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2018.36.15_suppl.tps8585","doi":"https://doi.org/10.1200/jco.2018.36.15_suppl.tps8585","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2018.36.15_suppl.tps8585","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2895922663","https://openalex.org/W3031542967","https://openalex.org/W4399519567","https://openalex.org/W2767459728","https://openalex.org/W4400978704","https://openalex.org/W2739859697","https://openalex.org/W3172638287","https://openalex.org/W2775537256","https://openalex.org/W2519019818","https://openalex.org/W2885151257"],"abstract_inverted_index":{"TPS8585":[0],"Background:":[1],"Over":[2],"40,000":[3],"patients":[4,59,124,170,322],"in":[5,58,94],"the":[6,81,224,229,282,312],"US/year":[7],"are":[8],"diagnosed":[9],"with":[10,30,60,65,125,162,177],"stage":[11,126],"III":[12,127],"NSCLC,":[13,128],"but":[14],"only":[15],"~25%":[16],"will":[17,90,111,140,242,253,275],"be":[18,56,141,243,254,276],"cured":[19],"by":[20,182,189,223],"standard":[21],"chemoradiation":[22],"(CRT).":[23],"Combining":[24],"checkpoint":[25],"inhibition":[26],"through":[27],"PD-L1":[28,232],"blockade":[29],"CRT":[31,69,89],"may":[32,70],"attenuate":[33],"tumor":[34,49,234],"related":[35],"immunosuppression":[36],"via":[37],"depletion":[38],"of":[39,44,116,150,153,185,195,200,231,284,310],"Tregs":[40],"and":[41,114,119,135,167,173,217,220,233,248,250,267,287,293,300,320],"clonal":[42],"expansion":[43],"effector":[45],"T-cells,":[46],"thereby":[47],"improving":[48],"immunogenicity.":[50],"Responses":[51],"to":[52,55,80,191,277],"immunotherapy":[53],"seem":[54],"higher":[57],"significant":[61],"cytoreduction,":[62],"such":[63],"as":[64,237],"radiation":[66],"(RT).":[67],"Further,":[68],"reveal":[71],"otherwise":[72],"hidden":[73],"antigens":[74],"that":[75],"can":[76],"present":[77],"additional":[78],"targets":[79],"reconstituting":[82],"immune":[83,251,288],"system.":[84],"Whether":[85],"anti-PD-L1":[86],"therapy":[87],"before":[88,118],"further":[91],"improve":[92],"outcomes":[93],"this":[95,201],"setting":[96],"is":[97,204],"unknown.":[98],"Methods:":[99],"This":[100],"phase":[101],"II":[102],"single":[103],"arm":[104],"Alliance":[105,146],"Foundation":[106],"Trials":[107],"study":[108,203,246,257,269],"(AFT-16,":[109],"NCT03102242)":[110],"evaluate":[112],"safety":[113,219],"efficacy":[115],"atezolizumab":[117,155,190,266,280],"after":[120,164,209],"definitive":[121],"CRT.":[122],"63":[123],"PS":[129],"0-1,":[130],"no":[131,136],"active":[132],"autoimmune":[133],"disease":[134,205],"underlying":[137],"organ":[138],"dysfunction":[139],"enrolled":[142],"at":[143,245,256,268,317],"15":[144],"US":[145],"sites.":[147],"Treatment":[148],"consists":[149],"4":[151,318],"cycles":[152,165,184],"neoadjuvant":[154,210,260],"1200":[156],"mg":[157],"IV":[158],"q":[159],"21":[160],"days":[161],"restaging":[163],"2":[166,183],"4.":[168],"Non-progressing":[169],"undergo":[171],"carboplatin":[172],"paclitaxel":[174],"(C/P)":[175],"weekly":[176],"60":[178],"Gy":[179],"RT":[180],"followed":[181,188],"C/P":[186],"consolidation":[187],"complete":[192],"one":[193],"year":[194],"therapy.":[196],"The":[197,303],"primary":[198],"endpoint":[199],"pilot":[202],"control":[206],"rate":[207],"(CR+PR+SD)":[208],"atezolizumab.":[211],"Secondary":[212],"endpoints":[213],"include":[214,228],"ORR,":[215],"PFS":[216],"OS,":[218],"QoL":[221],"assessed":[222],"EORTC":[225],"QLQ-30.":[226],"Correlatives":[227],"role":[230],"mutation":[235],"burden":[236],"predictive":[238,273],"biomarkers.":[239],"Tumor":[240],"tissue":[241],"obtained":[244],"entry,":[247,258],"plasma":[249],"cells":[252],"isolated":[255],"post":[259,262],"atezolizumab,":[261],"CRT,":[263],"during":[264],"adjuvant":[265],"end.":[270],"Additional":[271],"potential":[272],"biomarkers":[274],"define":[278],"how":[279],"affects":[281],"proportions":[283],"immunologic":[285],"subtypes":[286],"activation":[289],"using":[290],"flow":[291],"cytometry":[292],"T":[294],"cell":[295],"receptor":[296],"immunophenotyping,":[297],"multiplex":[298],"immunohistochemistry":[299],"cytokine":[301],"analysis.":[302],"trial":[304,313,327],"was":[305],"activated":[306],"on":[307],"11/1/17.":[308],"As":[309],"2/13/18,":[311],"has":[314],"been":[315,324],"opened":[316],"centers":[319],"8":[321],"have":[323],"enrolled.":[325],"Clinical":[326],"information:":[328],"NCT03102242.":[329]},"counts_by_year":[{"year":2023,"cited_by_count":2},{"year":2020,"cited_by_count":4}],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2018-09-27T00:00:00"}